Molecular Biomarkers and Imaging Markers in the Prediction, Diagnosis, and Prognosis of Heart Diseases
1Medical University of Lodz, Poland
2Umeå University, Sweden
3Department of Hypertension, Medical University of Lodz, Lodz 90-549, Poland
4Department of Medical Biotechnology, Medical University of Lodz, Poland
Molecular Biomarkers and Imaging Markers in the Prediction, Diagnosis, and Prognosis of Heart Diseases
Description
Heart disease describes a range of conditions that affect the heart muscle and is the leading cause of death in many countries. One in every four deaths in the U.S. occurs as a result of heart disease. Diseases under the heart disease umbrella include blood vessel diseases, such as coronary artery disease; heart rhythm problems (arrhythmias); congenital heart defects and cardiomyopathies, valve diseases, myocarditis and many others. Heart disease may also be a consequence of other diseases such as hypertension, diabetes, and rheumatic diseases.
Biomarkers are tools used to more accurately identify high-risk individuals, to speed the diagnosis, and to help in treatment and prognosis determination. Biomarkers can be classified based on different parameters, including their characteristics, such as imaging biomarkers (echocardiography, computed tomography, magnetic resonance imaging) or molecular biomarkers.
The goal of this Special Issue is to summarize new advances in both molecular and imaging biomarkers of heart diseases, especially in risk prediction, screening, diagnosis, and prognosis. Original research and review articles are both welcome in order to best understand the importance of different biomarkers in heart diseases.
Potential topics include but are not limited to the following:
- Advances in molecular biomarkers and heart diseases
- Advances in imaging biomarkers and heart disease
- The synergy of molecular and imaging biomarkers in predicting and detecting heart diseases
- The synergy of molecular and imaging biomarkers in the assessment of prognosis in heart disease
- Biomarkers for the evaluation of heart toxicity from chemo- and radiotherapy